COLUMBIA, Md.--Gene Logic, a preclinical discovery company that relies on its proprietary bioinformatics platform, has promoted Daniel Passeri to the position of senior vice-president of technology and program management. In addition, the company announced that it has received a USpatent for its restriction enzyme analysis of differentially expressed sequences (READS) gene expression tech nology.
Passeri was formerly Gene Logic's vice-president of business development and intellectual property management. In his new position he will build "a team responsible for the commercial direction and expansion of our alliances and partnerships," said Michael Brennan, the company's president and CEO. Brennan added, "Gene Logic has established and is continuing to build a powerful technology platform in the fields of genomics and bioinformatics for new drug discovery. Over the past eight months we have announced three major alliances based on this technology and expect the pace of our business development to accelerate further." The company's current partners include Procter & Gamble Pharmaceuticals, Japan Tobacco, and Akzo Nobel.
The newly patented READS technology is "the core of Gene Logic's accelerated drug discovery system," the company claimed, noting that it uses READS in "drug target and drug lead discovery programs and to generate genomic data for its database products." Inventors on the patent are Yatindra Prashar, Gene Logic's director of gene expression, and Sherman Weissman, Sterling Professor of Genetics and Medicine at the Yale School of Medicine.